Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
Go back to Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency| EAGLE CAPITAL GROWTH FUND, Inc. (NYSE: GRF) | Delayed: 10.22 -0.06 (0.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.28 | 52 Week High | $21.75 | |||
| Open | $10.22 | 52 Week Low | $6.41 | |||
| Day High | $10.22 | P/E | N/A | |||
| Day Low | $10.22 | EPS | $0.00 | |||
| Volume | 681 | |||||
| GRIFOLS SP ADR-B (NASDAQ: GRFS) | Delayed: 7.80 -0.08 (1.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.88 | 52 Week High | $35.35 | |||
| Open | $7.82 | 52 Week Low | $14.07 | |||
| Day High | $7.84 | P/E | N/A | |||
| Day Low | $7.77 | EPS | $0.00 | |||
| Volume | 157,912 | |||||
